TrialJAMA oncology2020

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

Maria Gonzalez-Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.